恩替卡韦抗病毒对TACE治疗的HBV DNA阴性乙型肝炎相关性肝癌的影响

doi:10.3969/j.issn.1672-5069.2018.01.023

摘要/Abstract

摘要： 目的探讨应用恩替卡韦预防治疗接受肝动脉化疗栓塞术（TACE）的乙型肝炎病毒（HBV）DNA阴性的乙型肝炎相关性肝细胞癌（HCC）患者对病毒激活的影响。方法将45例HBV DNA阴性乙型肝炎相关性HCC患者随机分为观察组23例和对照组22例。两组患者均在常规护肝治疗基础上接受TACE治疗,观察组于TACE治疗前1周开始应用恩替卡韦分散片抗病毒治疗,对照组未行抗病毒治疗。采用荧光定量PCR法检测血清HBV DNA,采用微粒发光法检测血清HBV标志物,使用全自动生化分析仪检测血生化指标。观察并比较两组TACE后血清HBV DNA转阳和肝衰竭发生率及生存率情况。结果在治疗24 w,观察组血清HBV DNA水平仍为<2 lg IU/mL,明显低于对照组的（4.10±2.86） lg IU/mL（P<0.01）,观察组HBV DNA转阳率为8.7%,明显低于对照组的36.4%（P<0.05）;观察组肝衰竭发生率为0.0%,对照组为22.7%,但两组差异无统计学意义（P>0.05）;在治疗12 w,观察组血清ALT为（56.75±20.74） IU/L,明显低于对照组的（125.78±42.75） IU/L,PTA为（48.65±8.26）%,明显高于对照组的（42.74±7.42）%（P<0.05）;在24 w,观察组血清ALT水平和Child-Pugh评分分别为（50.73±18.45）IU/L和（6.26±1.46）分,明显低于对照组的（97.48±30.56） IU/L和（7.84±1.65）分,PTA为（52.45±9.10）%,明显高于对照组的（39.56±6.78）%（均P<0.01）;两组近期临床疗效差异无统计学意义(P>0.05);观察组2 a生存率为69.6%,明显高于对照组的36.4%（P<0.05）。结论对接受TACE治疗的HBV DNA阴性的乙型肝炎相关性HCC患者,给予恩替卡韦抗病毒预防性治疗可以抑制HBV再激活,改善肝功能。

关键词: 肝细胞癌, 恩替卡韦, 血清HBV DNA阴性, 乙型肝炎病毒再激活

Abstract: Objective To investigate the effect of antiviral therapy with entecavir on HBV reactivation in serum HBV DNA negative hepatitis B virus infection-reduced patients with hepatocellular carcinoma （HCC） receiving transcatheter arterial chemoemholization（TACE）. Methods Forty-five patients with serum HBV DNA negative HBV-related HCC were randomly divided into observation group（n=23） and control group（n=22）. All patients in the two groups received TACE at base of conventional supporting treatment. Patients in observation group received entecavir before and after TACE. Serum HBV markers,HBV DNA and blood biochemical parameters were routinely assayed. The efficacy was evaluated by response evaluation criteria in solid tumors （RECIST） by world health organization. Results At the end of 24 w,serum HBV DNA in the observation group was still less than 2 lg IU/mL,while it increased to（4.10±2.86） lg IU/mL in the control group（P<0.05）;Serum HBV DNA positive rate in observation group was 8.7%,significantly lower than 36.4% in the control group（P<0.01）;The incidence of liver failure in observation group and control group were 0.0% and 22.7% respectively, without significant difference between the two groups（P>0.05）;At the end of 12 w,serum level of ALT in the observation group was （56.75±20.74） IU/L,significantly lower than （125.78±42.75） IU/L in the control group, and PTA was （48.65±8.26）%,significantly higher than （42.74±7.42）% in the control group （P<0.05）;At the end of 24 w,serum ALT level and Child-Pugh scores in observation group were （50.73±18.45） IU/L and（6.26±1.46）,respectively,significantly lower than （97.48±30.56） IU/L and（7.84±1.65） in the control group,and PTA was （52.45±9.10）%,significantly higher than （39.56±6.78） % in the control group （P<0.01）;There was no significant difference in clinical efficacy by RECIST between the two groups（P>0.05）;The 2-year survival rate in the observation group was 69.6%,significantly higher than 36.36% in the control group（P<0.05）,while there were no significant differences as respect to the 1-year survival rates between the two groups（P>0.05）. Conclusion Antiviral therapy with entecavir for serum HBV DNA negative HBV-related HCC patients can prevent the reactivation of hepatitis B virus, and improve liver function after TACE.

Key words: Hepatoma, Entecavir, Hepatitis B virus DNA-negative, Hepatitis B viral reactivation

占国清, 谭华炳, 李芳, 李儒贵, 张薇薇, 郭鹏. 恩替卡韦抗病毒对TACE治疗的HBV DNA阴性乙型肝炎相关性肝癌的影响[J]. 实用肝脏病杂志, 2018, 21(1): 96-99.

Zhan Guoqing, Tan Huabing, Li Fang, et al. Effect of antiviral therapy with entecavir on HBV reactivation in serum HBV DNA negative hepatitis B virus infection-reduced patients with hepatocellular carcinoma receiving transcatheter arterial chemoemholization[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 96-99.

参考文献

[1] Zhou JY,Zhang L,Li L. High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients:a case conttrol study. Virol J,2012,9:16.
[2] 肝细胞癌抗病毒治疗专家组. HBV/HCV相关性肝细胞癌抗病毒治疗专家共识.实用肝脏病杂志,2014,17（4）:Ⅰ-Ⅶ.
[3] Lao XM,Luo G,Ye LT,et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int,2013,33（4）:595-604.
[4] Peng JW,Lin GN,Xiao JJ,et al. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol,2012,8（4）:356-361.
[5] 柯阳,钟鉴宏,游雪梅,等.乙型肝炎病毒相关性肝细胞癌术后应用核苷（酸）类药物治疗.医学综述,2015,21（5）:807-811.
[6] 李小杉,肖静,高月霞. 原发性肝癌患者生存质量研究新进展,实用肝脏病杂志2011,14（3）:236-238.
[7] 周际昌. 实用肿瘤内科学. 2版,北京:人民卫生出版社,2003:451.
[8] 张立,马亚楠,张磊,等. 乙型肝炎相关性肝癌手术前后血清代谢轮廓分析及特征代谢物筛选. 中华肝胆外科杂志,2013,19（2）:81-87.
[9] Huang B,Li J,Zhou Z,et al. High prevalence of hepatitis B virus infection in multiple myeloma. Leuk Lymphoma,2012,53（2）:270-274.
[10] 郑盛,唐映梅,杨晋辉. 乙型肝炎相关性肝癌患者围手术期HBV DNA的变化及其影响因素. 中国肝脏病杂志（电子版）,2014,6（2）:38-43.
[11] Huang G,Lai EC,Lau WY,et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg,2013,257（3）:490-505.
[12] 王文欢,曹建彪. 乙型肝炎病毒相关性肝癌抗病毒治疗的现状.世界华人消化杂志,2013,21（5）:415-420.
[13] Huang L,Li J,Wan YL,et al. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol,2012,27（1）:158-164.
[14] Yeo W,Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol,2013,28（1）:31-37.
[15] 廖娟,王春晖,李肖,等. 经导管肝动脉化疗栓塞术对原发性肝癌患者细胞免疫及调节T细胞的影响. 肝脏,2011,16（3）:198-201.
[16] Jang JW,Choi JY,Bae SH,et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemolipiolization. Hepalology,2006,43（3）:233-240.
[17] 李荣宽,诸葛宇征,李振磊,等. 经肝动脉化疗栓塞术和经肝动脉栓塞术治疗对原发性肝癌患者乙型肝炎病毒DNA的影响. 中华临床医师杂志（电子版）,2011,5（20）:6109-6110.
[18] 周佳美,向慧玲,吕洪敏,等. 预防性抗病毒对TACE治疗的HBV DNA阴性乙肝相关性肝癌的效果. 天津医药,2013,41（9）:875-877.
[19] European Association For Study Of The Liver. EASL clinical practice guidelines:Management of chronic hepatitis B virus infection. J Hepatol,2012,57（1）:167-185.
[20] lok AS,Mcmahon BJ. Chronic hepatitis B:update 2009. Hepatology,2009,50（3）:661-662.
[21] 李星,江岚,邢艳芳,等. 拉米夫定预防化疗后乙型肝炎再活动致病毒耐药效果. 广东医学,2015,36（7）:1117-1119.